Skip to content

Repeated infusions of two antibodies delay viral rebound but don’t prevent it

Wongsakorn Napaeng/Shutterstock.com

Can HIV cure trials strike a balance between the need for meaningful data and participant safety?

Elle Aon/Shutterstock.com

Top 5 HIV treatment stories from CROI 2022

Professor Samir Gupta (top right) presenting a study on lenacapavir at CROI 2022.

Top 5 HIV cure and vaccine stories from CROI 2022

Professor Yvonne Bryson (top centre) presenting the HIV remission case at CROI 2022.

Top 5 stories on HIV prevention from CROI 2022

Professor Raphael Landovitz (bottom left) presenting the latest data on injected PrEP at CROI 2022.

Top 5 stories on HIV treatment and care in Africa from CROI 2022

Maya Jackson-Gibson presenting the study on COVID-19 and adverse birth outcomes at CROI 2022.

Why did an HIV vaccine fail in the Imbokodo trial?

Dr Glenda Gray (bottom right) at CROI 2022.

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two years later

Dr Deborah Persaud (top right) at CROI 2022.

One person remains undetectable without HIV drugs almost four years after using an antibody-based therapy

Dr Ole Schmeltz Søgaard at CROI 2022.